Concord Biotech Limited — JV/Acquisition, 02-04-2026: Acquisition

Concord Biotech has acquired a 100% stake in Celliimune Biotech Private Limited for ₹0.66 Cr. This strategic investment is set to advance Concord's pioneering research in DNA engineering for cancer therapeutics, focusing on developing innovative alternatives to conventional chemotherapy. The acquisition of Celliimune, a biopharmaceutical firm with no current turnover, transforms it into a wholly-owned subsidiary. This move significantly enhances Concord's product portfolio and R&D capabilities, aiming for long-term growth by innovating new cancer treatment therapies.